Back to results
US 9,066,886 B2Granted
Transdermal drug delivery system containing granisetron
AssigneeTaho Pharmaceuticals Ltd.
InventorHoo-Kyun Choi
Life of this patent
Estimating the term…
Abstract
Disclosed herein is a transdermal system in a matrix form capable of enhancing granisetron carrying efficiency and improving transdermal absorption while inhibiting recrystallization, which comprises: at least one transdermal enhancer selected from a group consisting of polyglyceryl-3 oleate, polyethyleneglycol-20 almond glyceride, polyethyleneglycol-12 palm kernel glyceride, isopropyl myristate and oleyl alcohol; and an acrylate polymer.
Claims5
A transdermal granisetron delivery system in a matrix form comprising:
- granisetron as an active ingredient and
- a matrix, including:
- an adhesive consisting of an acrylate polymer with a hydroxyl group and another acrylate polymer without any functional group in a ratio of 50 to 95:5 to 50;
- and
- at least one transdermal enhancer selected from a group consisting of polyglyceryl-3 oleate, polyethyleneglycol-20 (PEG-20) almond glyceride, polyethyleneglycol-12 (PEG-12) palm kernel glyceride, isopropyl myristate and oleyl alcohol,
- wherein
- granisetron is contained in an amount of 1 to 6 wt. % of the total weight of the matrix except a backing membrane and a release liner of the transdermal system;
- the transdermal enhancer is contained in an amount of 0.1 to 25 wt. % of the total weight of the matrix except a backing membrane and a release liner of the transdermal system and
- the transdermal granisetron delivery system has a drug permeation rate of not less than 10 μg/cm2/hr as measured on a hairless mouse's skin.
6 more elements
A transdermal granisetron delivery system in a matrix form comprising:
- granisetron as an active ingredient;
- and,
- a matrix, including:
- an adhesive consisting of an acrylate polymer with a hydroxyl group and another acrylate polymer without any functional group in a ratio of 4:1 to 1:1;
- and
- at least one transdermal enhancer selected from a group consisting of polyglyceryl-3 oleate, polyethyleneglycol-20 (PEG-20) almond glyceride, polyethyleneglycol-12 (PEG-12) palm kernel glyceride, isopropyl myristate and oleyl alcohol,
- wherein
- granisetron is contained in an amount of 1 to 6 wt. % of the total weight of the matrix except a backing membrane and a release liner of the transdermal system;
- the transdermal enhancer is contained in an amount of 0.1 to 25 wt. % of the total weight of the matrix except a backing membrane and a release liner of the transdermal system and
- the transdermal granisetron delivery system has a drug permeation rate of not less than 10 μg/cm2/hr as measured on a hairless mouse's skin.
7 more elements
Dependencies are inferred from the claim text.